Debunking the Myth That 'Fragile X Syndrome' Cannot be Treated

by Dr. Trupti Shirole on  February 19, 2017 at 8:51 AM Genetics & Stem Cells News
RSS Email Print This Page Comment bookmark
Font : A-A+

Fragile X Syndrome (FXS) is the most common cause of inherited intellectual disability and the most common known genetic cause of autism or autism spectrum disorders.
 Debunking the Myth That 'Fragile X Syndrome' Cannot be Treated
Debunking the Myth That 'Fragile X Syndrome' Cannot be Treated

Approximately one in 3,000 to 4,000 individuals has FXS. It causes a range of developmental problems including learning disabilities and cognitive impairment.

Usually, males are more severely affected by this disorder than females.

The absence of clinical medicine to treat Fragile X Syndrome does not mean it is not amenable to other forms of care, suggested experts debunking myths about the inherited condition.

"For something that is not treatable by medicine, you tend to think nothing can be done. The doctor's job is to get somebody better. The real myth is there is no chemical medicine so nothing can be done," Samir Dalwai, Indian Academy of Pediatrics, Mumbai chapter, told IANS.

The awareness level in India with respect to other countries is considerably low, says Shalini Kedia, chairperson, Fragile X Society of India.

"It is necessary for spreading awareness about the syndrome among the medical fraternity especially pediatricians and gynecologists as well as parents and couples planning to have a child, so that children with Fragile X Syndrome are detected early in life," Kedia told IANS.

There is no medication that has a benefit specifically for fragile X syndrome. Drugs are commonly used to treat symptoms of attention deficit and hyperactivity, anxiety, and aggression and so, supportive management becomes necessary.

Kedia said in developed countries like the US, toddlers at the age of 36-42 months are detected with Fragile X Syndrome whereas, in India, children with Fragile X Syndrome are detected at a later age of six-eight years or even later. This leads to a huge gap in their treatment cycle.

Dalwai hoped guidelines on FXS would soon be available.

"We have a chapter of neurodevelopmental pediatrics and we just came out with guidelines on autism, ADHD. We would be very happy to come out with guidelines on FXS. Once we have looked at autism, after that next thing should be to look at specific causes of autism and intellectual disability," he added.

Source: IANS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...